Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
|Eligible Ages||19 Years and Over|
Inclusion criteria. 1. Patients ≥ 19 years. 2. Relapsed and/or refractory multiple myeloma patients. 3. Patients who had received KRd combination chemotherapy from February, 2018 to February, 2020. Exclusion criteria. 1. Patient who had not been treated with KRd combination therapy from the first cycle of treatment. 2. Patients who had received KRd combination chemotherapy before February, 2018 and after February, 2020.
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
|Dong-A University Hospital|
The person who is responsible for the scientific and technical direction of the entire clinical study.
|Sung-Hyun Kim, MD, Ph.D|
|Principal Investigator Affiliation||Dong-A University Hospital|
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
|Overall Status||Not yet recruiting|
The disease, disorder, syndrome, illness, or injury that is being studied.
|Multiple Myeloma in Relapse, Multiple Myeloma, Refractory|
Key study variables: Demographic data, ISS, R-ISS, cytogenetic abnormalities on FISH and G-banding, previous treatment regimens, response to previous treatment regimens, existence of extramedullary plasmacytoma, MM-related symptoms, whether or not M protein has increased twice or more in 2-3 months at the time of KRd commencement, response to KRd therapy, duration of KRd treatment, adverse events during KRd therapy, disease progression and progression date, survival, and censored date or day of death
: Relapsed and/or refractory multiple myeloma
Multiple myeloma in relapsed but not refractory, relapsed and refractory, and primary refractory status
Drug: - Carfilzomib
Intravenous carfilzomib, lenalidomide, dexamethasone
Drug: - Lenalidomide
Drug: - Dexamethasone
Oral or intravenous
This trial has no sites locations listed at this time. If you are interested in learning more, you can contact the trial's primary contact:
Ji Hyun Lee, MD, Ph.D
For additional contact information, you can also visit the trial on clinicaltrials.gov.